Key Takeaways One shot a month of an experimental drug yielded promising results in a new clinical trialThe drug, called ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...